Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • p38 MAPK
    (11)
  • Autophagy
    (7)
  • Apoptosis
    (3)
  • PKC
    (3)
  • COX
    (2)
  • Calcium Channel
    (2)
  • ERK
    (2)
  • PKA
    (2)
  • ROCK
    (2)
  • Others
    (8)
Filter
Search Result
Results for "

p 38

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    27
    TargetMol | Inhibitors_Agonists
  • Peptide Products
    4
    TargetMol | Peptide_Products
  • Natural Products
    7
    TargetMol | Natural_Products
  • Recombinant Protein
    2
    TargetMol | Recombinant_Protein
  • Antibody Products
    3
    TargetMol | Antibody_Products
Cgp 38560
Cgp38560,Cgp-38560
T30829122088-76-0
CGP 38560 is a potent renin inhibitor.
  • Inquiry Price
Size
QTY
Fasudil hydrochloride
HA-1077 hydrochloride, Fasudil HCl, Fasudil (HA-1077) HCl, AT-877 hydrochloride
T3060105628-07-7
Fasudil hydrochloride (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK with Ki of 0.33 μM, 1.0 μM, 9.3 μM and 55 μM, respectively.
  • Inquiry Price
Size
QTY
Flavokawain A
Flavokavain A
T3S07373420-72-2
NSC-37445 has anti-tumor activity, such as inhibits growth of bladder tumor cells in a nude mice model , prevents the recurrence and progression of non-muscle-invasive urothelial cell carcinoma. NSC-37445 can significantly reduce the expression of CDK1-inhibitory kinases, Myt1 and Wee1, and cause cyclin B1 protein accumulation leading to CDK1 activation in T24 cells. 3. Flavokawain A (Flavokavain A) may exert anti-inflammatory responses by suppressing LPS-induced expression of pro-inflammatory mediators via blockage of NF-κB-AP-1-JNK p38 MAPK signaling pathways in the murine macrophages.
  • Inquiry Price
Size
QTY
bongkrekic acid
Bongkrek Acid
T3606711076-19-0
Bongkrekic acid (Bongkrekic Acid (ammonium salt)) is a mitochondrial toxin secreted by Burkholderia gladioli that inhibits adenine nucleotide translocase (ANT).Bongkrekic acid Bongkrekic acid Bongkrekic acid induces extracellular traps in neutrophils through signaling mediated by p38, ERK, PAD4, and P2X1.
  • Inquiry Price
7-10 days
Size
QTY
Butein
2',3,4,4'-tetrahydroxy Chalcone
T6427487-52-5
Butein is a cAMP-specific PDE inhibitor, protein tyrosine kinase inhibitor, and SIRT1 activator. It sensitizes HeLa cells to Cisplatin by targeting FoxO3a via the AKT and ERK p38 MAPK pathways.
  • Inquiry Price
Size
QTY
SD-169
SD 169
T76611670-87-7
SD-169 (SD 169) is a selective and ATP competitive the MAP kinases p38α and p38β inhibitor.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Fasudil
HA-1077, AT877
T1606103745-39-7
Fasudil (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK.
  • Inquiry Price
Size
QTY
AZ304
T5172942507-42-8
AZ304 is an ATP-competitive dual BRAF kinase inhibitor, effectively inhibiting BRAF (WT), BRAF (V600E), and wild-type CRAF [IC50s: 79 38 68 nM].
  • Inquiry Price
Size
QTY
Isofraxidin
Phytodolor, 6,8-Dimethoxyumbelliferone
T5S0045486-21-5
1. Isofraxidin (Phytodolor) protects leukemia cells from radiation-induced apoptosis via ROS mitochondria pathway in a p53-independent manner. 2. Isofraxidin has a protective effect against LPS-induced ALI, and the protective effect of Isofraxidin seems to result from the inhibition of COX-2 protein expression in the lung, which regulates the production of PGE2. 3. Isofraxidin possesses significant analgesic and anti-inflammatory activities that may be mediated through the regulation of pro-inflammatory cytokines, TNF-α and the phosphorylation of p38 and ERK1 2.
  • Inquiry Price
Size
QTY
SU9516
T6167377090-84-1
SU9516 is a potent CDK2 inhibitor with an IC50 of 22 nM and also inhibits CDK1 and CDK4, with IC50s of 40 nM and 200 nM, respectively.
  • Inquiry Price
Size
QTY
anemarsaponin B
T7030139051-27-7
Anemarsaponin B has anti-inflammatory effect in LPS-treated RAW 264.7macrophages, the effect is associated with the inhibition of NF-κB transcriptional activity, possibly via the p38 MAP kinase pathway. Anemarsaponin B can inhibit PAF-induced rabbit platelet aggregation in vitro.
  • Inquiry Price
Size
QTY
p38 mapk inhibitor
T36010219138-24-6In house
p38 MAPK inhibitor is a potent inhibitor of p38 MAP kinase (IC50 = 35 nM). It inhibits senescence induced by the oncogene RAS.
  • Inquiry Price
6-8 weeks
Size
QTY
p38 MAPK-IN-2
T11241635725-16-5
p38 MAPK-IN-2 is a potent inhibitor of p38 kinase.
  • Inquiry Price
6-8 weeks
Size
QTY
p38-α MAPK-IN-1
T12347443913-15-3
p38-α MAPK-IN-1 is a MAPK14 (p38-α) inhibitor with an IC50 of 2300 nM in the EFC displacement assay and 5500 nM in the HTRF assay.
  • Inquiry Price
6-8 weeks
Size
QTY
p38 MAPK-IN-1
T164241006378-90-0
p38 MAPK-IN-1 is a novel selective p38 MAPK inhibitor with high potency, long duration, and low clearance, which reduces inflammatory responses by inhibiting LPS-induced TNF-α production.
  • Inquiry Price
8-10 weeks
Size
QTY
Dehydrocorydaline nitrate
T2S236213005-09-9
1. Dehydrocorydaline(DHC) not only inhibits antibody-mediated allergic reactions but also influences cell-mediated allergic reactions, and the inhibitory effect of Corydalis Tuber on allergic reactions may be partially attributed to DHC. 2. Dehydrocorydal
  • Inquiry Price
7-10 days
Size
QTY
DPX-3778
T3157360575-85-1
DPX-3778 is the triethanolamine salt of 3-(p-chlorophenyl)-6-methoxy-s-triazine-2,4(1H,3H) dione, at concentrations of 0.124-2.48 μM enhanced ca. 4-5-fold the proliferation of tobacco (Nicotiana tabacum L. cv. Wisconsin 38) callus cultured in the presence
    6-8 weeks
    Inquiry
    (s)-p38 mapk inhibitor iii
    (S)-p38 MAPK Inhibitor III
    T35420581098-48-8
    (S)-p38 MAPK inhibitor III is a methylsulfanylimidazole that inhibits p38 MAP kinase (IC50 = 0.90 μM in vitro). It is cell-permeable, potently blocking the release of TNF-α and IL-1β from human peripheral blood mononuclear cells (IC50s = 0.37 and 0.044 μM, respectively).
    • Inquiry Price
    6-8 weeks
    Size
    QTY
    p38 MAP Kinase Inhibitor IV
    p38 MAPK Inhibitor IV
    T360111638-41-1
    p38 MAPK inhibitor IV is an ATP-competitive inhibitor of p38 MAP kinases with IC50 values of 0.13, 0.55, 5.47, and 8.63 μM for p38α, p38β, p38x, and p38δ, respectively, in vitro.[1] It also inhibits LPS-induced TNF-α and IL-1β cytokine production (IC50s = 22 and 44 nM, respectively) in human peripheral blood mononuclear cells.
    • Inquiry Price
    6-8 weeks
    Size
    QTY
    ROC-0929
    T384461048660-43-0
    ROC-0929 (compound 13a) is a potent and selective inhibitor of secreted phospholipases A2 (sPLA2s), targeting hGX with an IC50 of 80 nM. It efficiently inhibits the phosphorylation of ERK1 2 and p-38. sPLA2s, part of the disulfide-rich, Ca2+-dependent enzyme family, catalyze the hydrolysis of glycero-phospholipids at the sn-2 position, releasing a fatty acid and a lysophospholipid. ROC-0929 is promising for research on inflammation-related diseases.
    • Inquiry Price
    Size
    QTY
    YHO-13177
    YHO 13177, YHO13177
    T4595912287-56-0
    YHO-13177 is a potent and specific inhibitor of BCRP, which enhances the cytotoxicity of SN-38 in cancer cells without affecting P-glycoprotein–mediated paclitaxel resistance in [MDR1]-transduced human leukemia [K562] cells.
    • Inquiry Price
    Size
    QTY
    CGP-53716
    T67442152459-94-4
    The growth factors, platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF) play major roles in enhanced smooth muscle cells growth in rodent blood vessels after vascular injury. Tyrosine kinase inhibition has been shown to be effective in blocking tyrosine phosphorylation at the PDGF and bFGF receptors in cultured fibroblast and vascular smooth muscle cells which in turn inhibits their proliferation[1]. CGP 53716 is a specific PDGFR tyrosine kinase inhibitor on SMC (smooth muscle cell) proliferation and migration in vitro and in neointimal formationin vivo[3]. CGP 53716 inhibited serum-induced cell growth in RASMC (rat aortic smooth muscle cells). And it completely blocked PDGF-BB tyrosine receptor autophosphorylation in RASMC and 3T3 cells, PDGF-BB-induced phosphorylation of mitogen-activated protein kinase at 1 μM in RASMC and inhibited PDGF-BB-induced c-Fos protein expression at 1 μM in RASMC; consistent with inhibition of PDGF-BB-induced DNA synthesis. Further, CGP 53716 inhibited PDGF-BB-, bFGF- and EGF-induced DNA synthesis in a concentration-dependent manner in each cell line. And it showed a 2- to 4-fold selectivity for PDGF-BB-stimulated DNA synthesis over bFGF or EGF in RASMC or 3T3 cells[1]. CGP 53716 inhibited dose dependently tyrosine phosphorylation of both the known PDGFRs: the PDGFR-α and PDGFR-β. After rat carotid artery ballooning injuryin vivo, the migration of alpha-actin-positive cells on the luminal side of internal elastic lamina was decreased with 50 mg kg day of CGP 53716 from 38 ± 10 (control group) to 4 ± 2. Intima media ratio was inhibited by 40% after 14 days in the CGP 53716-treated group (P=0.028) after rat aortic denudation[3].
      7-10 days
      Inquiry
      PACAP (1-38) free acid TFA
      T81571
      PACAP (1-38) free acid TFA, an endogenous neuropeptide, effectively enhances antral motility and somatostatin secretion, while concurrently suppressing gastrin secretion and promoting the release of vasoactive intestinal polypeptide, gastrin-releasing peptide, and substance P. Additionally, it amplifies N-methyl-D-aspartate receptor function and brain-derived neurotrophic factor expression via RACK1 [1] [2].
      • Inquiry Price
      Size
      QTY
      PACAP (1-38) free acid
      T81572129405-61-4
      PACAP (1-38) free acid, an endogenous neuropeptide, potently modulates gastrointestinal and neuroendocrine functions. It enhances antral motility, increases somatostatin secretion, and stimulates the release of vasoactive intestinal polypeptide, gastrin releasing peptide, and substance P, while concurrently inhibiting gastrin secretion. Additionally, it augments N-methyl-D-aspartate receptor function and upregulates brain-derived neurotrophic factor expression via RACK1 [1] [2].
      • Inquiry Price
      Size
      QTY